Core Viewpoint - The article discusses the significant decline in sales of the skincare product "可复美胶原棒2.0" (Kefumei Collagen Stick 2.0) due to quality concerns raised by external parties, leading to a broader impact on the parent company, 巨子生物控股有限公司 (Juzi Biotech) [2][3][4]. Sales Performance - Sales of the Kefumei Collagen Stick 2.0 have dropped by 60% to 70% compared to April 2023, severely affecting individual distributors like 李吉 (Li Ji) [3][5]. - The product's price has fallen from 178 yuan to 150 yuan per box, resulting in losses for distributors who had previously stocked up at higher prices [5][11]. - The company's performance during the "6·18" sales event saw a decline in rankings and sales, marking the first time in three years that it did not disclose sales data for this period [4][9][10]. Market Impact - The controversy began with a report from a beauty influencer questioning the collagen content in the product, which led to a significant drop in consumer trust and sales [5][6]. - The number of influencers promoting the product decreased by 32% during the "6·18" period compared to the previous year, indicating a shift in marketing dynamics [7][9]. Company Response - 巨子生物 acknowledged the limitations of its quality standards and testing methods in a public statement, indicating a need for improvement [6][10]. - Despite the challenges, the company maintains its revenue targets for 2025 and expresses confidence in recovering from the losses incurred during the sales event [4][10]. Financial Overview - 巨子生物 reported a compound annual growth rate of 52.8% in revenue from 2022 to 2024, with a net profit growth rate of 43.5% [10][12]. - The company’s stock price has seen fluctuations, dropping nearly 40% since May 24, but showed a slight recovery following announcements of share buybacks by its major shareholder [13][14].
风波中的可复美：渠道商的囤货卖不出去了